Raiffeisen Bank International AG Boosts Stock Holdings in Humana Inc. $HUM

Raiffeisen Bank International AG lifted its position in Humana Inc. (NYSE:HUM) by 5.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,808 shares of the insurance provider’s stock after purchasing an additional 322 shares during the period. Raiffeisen Bank International AG’s holdings in Humana were worth $1,624,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HUM. Vanguard Group Inc. raised its position in shares of Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after acquiring an additional 1,143,662 shares during the period. AQR Capital Management LLC increased its stake in shares of Humana by 3,257.5% in the 1st quarter. AQR Capital Management LLC now owns 1,162,600 shares of the insurance provider’s stock valued at $307,624,000 after purchasing an additional 1,127,973 shares in the last quarter. Leith Wheeler Investment Counsel Ltd. increased its stake in shares of Humana by 661.7% in the 2nd quarter. Leith Wheeler Investment Counsel Ltd. now owns 1,038,703 shares of the insurance provider’s stock valued at $253,942,000 after purchasing an additional 902,340 shares in the last quarter. Nuveen LLC acquired a new position in shares of Humana during the 1st quarter worth approximately $171,220,000. Finally, Dodge & Cox grew its stake in Humana by 5.5% in the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock valued at $2,845,830,000 after acquiring an additional 557,175 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

HUM opened at $234.55 on Wednesday. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $315.35. The firm has a market capitalization of $28.21 billion, a PE ratio of 18.00, a PEG ratio of 1.71 and a beta of 0.42. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average price is $268.77 and its 200 day moving average price is $257.69.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.29. Humana had a net margin of 1.28% and a return on equity of 13.67%. The company had revenue of $32.65 billion during the quarter, compared to the consensus estimate of $31.99 billion. During the same quarter in the prior year, the firm earned $4.16 EPS. Humana’s quarterly revenue was up 11.1% on a year-over-year basis. As a group, sell-side analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.5%. Humana’s dividend payout ratio (DPR) is presently 33.18%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Truist Financial reduced their price objective on shares of Humana from $300.00 to $285.00 and set a “hold” rating for the company in a research report on Monday, November 10th. Mizuho upped their price target on shares of Humana from $300.00 to $345.00 and gave the stock an “outperform” rating in a research report on Thursday, October 9th. Wolfe Research raised their price target on shares of Humana from $283.00 to $313.00 and gave the company an “outperform” rating in a research note on Monday, October 6th. Wall Street Zen lowered Humana from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Bank of America increased their target price on Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a report on Friday, October 10th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Humana presently has an average rating of “Hold” and an average price target of $298.39.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.